New combo therapy aims to wipe out rectal cancer before surgery
NCT ID NCT06577194
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new approach for people with locally advanced rectal cancer. Participants first receive a short course of radiation, followed by a combination of immunotherapy (sintilimab and IL-2) and chemotherapy (CAPOX). The goal is to see if this treatment can make the tumor completely disappear before any surgery is needed. The study will enroll 35 adults aged 18 to 70.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (PD-1 antibody) plus IL-2 plus CAPOX chemotherapy
What this could lead to
If successful, this combination could increase the chance of complete tumor disappearance before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong
This is a small, early-phase trial with only 35 people, so results may not apply broadly. The combination of treatments may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-••••